Thermo Fisher Scientific Inc
NYSE:TMO
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.7B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.9B USD |
Loading...
|
|
| DE |
|
Merck KGaA
XETRA:MRK
|
54.4B EUR |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.3B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.8B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.9B CNY |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Thermo Fisher Scientific Inc
Glance View
Thermo Fisher Scientific Inc. stands as a towering entity in the life sciences industry, intricately weaving together science, technology, and business to drive scientific progress and innovation. Founded through a merger of Thermo Electron and Fisher Scientific in 2006, the company has grown exponentially to become a formidable partner for researchers, academicians, and clinicians worldwide. Its business model is built around a broad portfolio of offerings, including laboratory instruments, analytical tools, and consumables, which are crucial for research and quality control. By emphasizing research and development, Thermo Fisher has consistently advanced its technologies, ensuring that its solutions remain indispensable to ventures in pharmaceuticals, biotechnology, and diagnostics. The strategic acquisition of complementary businesses has been a key facet of Thermo Fisher’s growth, fortifying its position across various scientific fields. In essence, the company thrives on understanding the increasingly complex demands of the scientific community. It generates revenue by capitalizing on its diverse product lineup, subscription-based services, and personalized solutions that cater to specific client needs—ranging from equipment used to perform intricate genomic sequencing to reagents required for advanced laboratory experiments. Thus, Thermo Fisher sustains its financial health through a combination of one-time sales and recurring revenue streams, a strategy that not only reflects its adaptability but also ensures long-term profitability and market leadership in the ever-evolving landscape of scientific research.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Thermo Fisher Scientific Inc is 41.5%, which is above its 3-year median of 40.7%.
Over the last 3 years, Thermo Fisher Scientific Inc’s Gross Margin has decreased from 42.2% to 41.5%. During this period, it reached a low of 39.7% on Jul 1, 2023 and a high of 42.2% on Dec 31, 2022.